As of 2025-07-04, the Intrinsic Value of Laboratorios Farmaceuticos ROVI SA (ROVI.MC) is 46.58 EUR. This ROVI.MC valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 55.65 EUR, the upside of Laboratorios Farmaceuticos ROVI SA is -16.30%.
The range of the Intrinsic Value is 33.16 - 81.32 EUR
Based on its market price of 55.65 EUR and our intrinsic valuation, Laboratorios Farmaceuticos ROVI SA (ROVI.MC) is overvalued by 16.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 33.16 - 81.32 | 46.58 | -16.3% |
| DCF (Growth 10y) | 39.30 - 91.32 | 53.91 | -3.1% |
| DCF (EBITDA 5y) | 29.50 - 35.64 | 32.97 | -40.8% |
| DCF (EBITDA 10y) | 37.26 - 47.55 | 42.58 | -23.5% |
| Fair Value | 68.32 - 68.32 | 68.32 | 22.76% |
| P/E | 44.00 - 71.49 | 51.88 | -6.8% |
| EV/EBITDA | 22.46 - 44.24 | 30.87 | -44.5% |
| EPV | 44.85 - 60.07 | 52.46 | -5.7% |
| DDM - Stable | 26.03 - 84.85 | 55.44 | -0.4% |
| DDM - Multi | 30.37 - 78.02 | 43.85 | -21.2% |
| Market Cap (mil) | 2,851.51 |
| Beta | 0.49 |
| Outstanding shares (mil) | 51.24 |
| Enterprise Value (mil) | 2,938.73 |
| Market risk premium | 7.44% |
| Cost of Equity | 8.62% |
| Cost of Debt | 4.25% |
| WACC | 8.42% |